Kathleen Madden on Managing AEs From Targeted Therapies for Melanoma
Kathleen M. Madden, MSN, FNP-BC, AOCNP
Kathleen M. Madden discusses the management of adverse events (AEs) with BRAF and MEK inhibitors for the treatment of patients with melanoma.
Kathleen M. Madden, MSN, FNP-BC, AOCNP®, APHN, from Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the management of adverse events (AEs) with BRAF and MEK inhibitors for the treatment of patients with melanoma.
The entire process starts with trust and a good relationship between the patient and nurse, Madden says. Patients need to be taught that no matter how minor an issue may seem on the surface, it could develop into something more significant. On a similar note, patients don’t always understand the significance of a side effect before treatment begins.
Madden says in her workflow, she and other nurses appreciate when patients call if they have a question, but they don’t always call early enough.